immunotherapy | CAR-T Therapy in China
페이지 정보
Author HK HIS Date19-09-16 18:18 View892 Comment0관련링크
https://www.nature.com/articles/nrclinonc.2017.128/tables/2#t2
본문
CAR-T cell therapy may include non-Hodgkin's lymphoma (NHL) in certain blood cancers (lymphomas that do not get better after chemotherapy or stem cell transplantation), such as lymphoma and leukemia, and leukemias include chronic lymphocytic leukemia (CLL) And acute lymphocytic leukemia (ALL).
Currently in China, in clinical trials, it was carried out in patients with T-cell hematopoietic and lymphoid malignancies. From the perspective of CAR-T cells in the treatment of Chinese and American blood tumors, most of the Chinese and American CAR-T have shown good therapeutic effect. It reached 66.9% (China) and 68.5% (US) respectively.
The five cities with the most active clinical research on CAR-T cells in China are Beijing 38, Shanghai 25, Chongqing 16, Guangzhou 15 and Shenzhen, and the top five cities in the United States are Houston (48 studies). , Philadelphia (34 studies), New York (16 studies), Du Arte (14 studies), and Seattle (14 studies). China's clinical research on CAR-T cells is growing at a relatively rapid pace.
In numerical terms, China saw a 133% increase in 2017 compared to the United States.
On December 31, 2017, on the website clinicaltrials.gov, CAR-T treatment accounted for 91.1% of the worldwide CAR-T treatment, and China entered 317 clinical trials. (Other countries include the UK, Italy, Sweden, Germany, Spain, Japan, Israel, and Australia, which account for less than 10% of global non-US).
HK HIS offers US FDA-approved CAR-T treatment and treatment opportunities for current clinical trials. Please contact HK HIS.
